PDE4-IN-13

• UNSPSC Description:

  PDE4-IN-13 is a PDE4 inhibitor with an IC50 of 1.56 μM. PDE4-IN-13 shows anti-inflammatory and antioxidant properties， and can be used for chronic obstructive pulmonary disease (COPD) research[1].

• Target Antigen:

  Phosphodiesterase (PDE)

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/pde4-in-13.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(C1=CC=C(O)C(O)=C1)/C=C/C2=CC=C(OC)C(OCC3CC3)=C2

• Molecular Weight:

  340.37

• References & Citations:

  [1]Youzhi Wang, et al. Design and synthesis of a novel class of PDE4 inhibitors with antioxidant properties as bifunctional agents for the potential treatment of COPD. Eur J Med Chem. 2023 Aug 5;256:115374.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported